Global Oral Expectorant Market, By Type (Drug, OTC, Herbal, Others), Route of Administration (Oral, Inhalational, Others), End-User (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2031.
Oral Expectorant Market Analysis and Size
Growing cases of dry cough which causes dryness in the throat drive the expectorants market. However, the easy availability of expectorants OTC drugs and rising respiratory disease prevalence will boost the expectorants market. Medical advancements that involve ongoing drug discovery, and government and non-government organizational initiatives boost the market growth.
Data Bridge Market Research analyzes that the global oral expectorant market which was USD 4243.60 million in 2023, is likely to reach up to USD 5375.67 million by 2031, and is expected to undergo a CAGR of 3.1% during the forecast period. This indicates the market value. “Drug” dominates the type segment of the market due to the rising respiratory disease prevalence. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Drug, OTC, Herbal, Others), Route of Administration (Oral, Inhalational, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Merck KGaA (Germany), Novartis AG (Switzerland), Beckman Coulter Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Biocon (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Reckitt Benckiser Group PLC (U.K.), Acadia Pharmaceuticals Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Expectorants are the medical agents that help in clearing or bringing up mucus from the lungs, bronchi, and trachea. They act by promoting drainage of mucus from the lungs by thinning the mucus and reducing the respiratory tract's irritation by lubrication. They also help to relieve chest congestion caused by colds, allergies, and flu.
Global Oral Expectorant Market Dynamics
Drivers
- Increased Initiatives by Government and Market Players
The increasing number of efforts and initiatives that are being initiated by the government and major market leaders all over the world are boosting market growth. Governments in many countries have launched several initiatives towards launching more and more expectorants that will help in the betterment of the patients. Thus, these factors drive the market growth.
- Rising Demand for Oral Drugs
The market is witnessing a surge in demand for oral drugs, which serves as a key driver for its growth. The rising preference for oral medications can be attributed to their convenience, ease of administration, and patient compliance. Oral drugs offer several advantages, including faster onset of action, improved bioavailability, and reduced need for invasive procedures. Moreover, the development of innovative formulations and advancements in drug delivery technologies have further fueled the demand for oral expectorants. This growing trend of oral drug consumption is expected to significantly propel the market in the future.
Opportunity
- Increased FDA Approvals
Increased FDA approvals present a significant opportunity in the market. The stringent regulatory standards and rigorous approval processes enforced by the FDA ensure the safety, efficacy, and quality of expectorant drugs. As the FDA continues to grant approvals for new expectorant formulations, it instills confidence among healthcare professionals and patients regarding their effectiveness. These approvals open avenues for pharmaceutical companies to introduce innovative products and expand their market presence. The growing number of FDA-approved expectorants enables healthcare providers to offer a broader range of treatment options, addressing various respiratory conditions. This opportunity fosters market growth and enhances patient care in the expectorants sector.
Restraint/Challenge
- Increased Side Effects
Increased side effects pose a significant challenge in the market. While expectorants are commonly used to relieve respiratory congestion, they may also be associated with adverse effects such as dizziness, nausea, gastrointestinal disturbances, and allergic reactions. The occurrence of these side effects can impact patient compliance and overall treatment outcomes. Furthermore, severe or unexpected side effects may lead to safety concerns, resulting in regulatory scrutiny and potential market restrictions. Pharmaceutical companies need to invest in research and development to minimize side effects and improve the safety profile of expectorant drugs. Addressing this challenge is crucial to maintain patient trust and sustain the growth of the market.
Recent Development
- In March 2018, Perrigo Company plc. received FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the guaifenesin market growth during the forecast period.
Global Oral Expectorant Market Scope
The oral expectorant market is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Drug
- OTC
- Herbal
- Others
Route of Administration
- Oral
- Inhalational
- Others
End-User
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Oral Expectorant Market Regional Analysis/Insights
The oral expectorants market is analyzed and market size insights and trends are provided by country, type, route of administration, distribution channel, and end-user as referenced above.
The countries covered in the market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, and rest of Middle East and Africa.
North America is expected to dominate the market due to the strong base of healthcare facilities, the strong presence of major players in the market, increasing inclination towards respiratory medicines, and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The oral expectorant market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the oral expectorant market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the oral expectorant market.
Competitive Landscape and Global Oral Expectorant Market Share Analysis
The oral expectorant market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the oral expectorant market.
Some of the major players operating in the oral expectorant market are:
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Beckman Coulter Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Biocon (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Reckitt Benckiser Group PLC (U.K.)
- Acadia Pharmaceuticals Inc. (U.S.)
SKU-